A Phase Ib, Dose Escalation, Multiple Dose Trial With HuMax-IL8 in Patients With Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors

Trial Profile

A Phase Ib, Dose Escalation, Multiple Dose Trial With HuMax-IL8 in Patients With Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs HuMax IL8 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; Cormorant Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 04 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top